Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Gilead Science’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for ...

A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to change their approach toward handling ...